SSEA-4 is epitopes on related glycosphingolipids (GSLs), termed GL-7. The GSLs of globo-series feature a Galα1–4Gal linkage to lactosylceramides, and this linkage is catalyzed by the lactosylceramide 4-alpha-galactosyltransferase, encoded by the A4GALT gene. "stage-specific embryonic antigen-4" (SSEA-4) is cell-surface marker widely used to define human embryonic stem cells (hESCs). GSLs also have been observed in tumors: SSEA-4 is expressed not only on breast cancer cells but also on breast cancer stem cells. high-level expression of SSEA-4 is observed in renal cell carcinoma.
|CAT||Product Name||Target Species||Antibody Clone||Antibody Host||Receptor Construction||Vector Type||Targeting Cell Type||Inquiry & Datasheet|
|CAR-LC001||Anti-SSEA4 h(41BB-CD3ζ) CAR, pCDCAR1||Human||Mouse||scFv-41BB-CD3ζ||Lentiviral||T cell|
|CAT||Product Name||Clone||Promotor||Packaging System||Targeting Diseases||Inquiry & Datasheet|
|VP-CAR-LC509||Lenti-SSEA4 CAR (scFv-41BB-CD3ζ ) Viral Particle||EF1a||Lentivirus|
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE